New breast cancer drug aims to match gold standard in major trial
NCT ID NCT04514419
Summary
This study is testing if a new drug called HS627 works as well as the standard drug pertuzumab when combined with other treatments before surgery for early or locally advanced HER2-positive breast cancer. The goal is to shrink or eliminate the tumor before the operation. About 408 participants were randomly assigned to receive either HS627 or pertuzumab for about 12 weeks, followed by surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
Conditions
Explore the condition pages connected to this study.